Graham A, Hasani A, Alton E W, Martin G P, Marriott C, Hodson M E, Clarke S W, Geddes D M
Ion Transport Laboratory, National Heart and Lung Institute, London, UK.
Eur Respir J. 1993 Oct;6(9):1243-8.
In cystic fibrosis (CF) airway epithelial sodium absorption is increased 2-3 fold. Since sodium absorption is inhibited by the sodium channel blocker amiloride, our aim was to assess its therapeutic benefit in cystic fibrosis. A randomized, double-blind, placebo-controlled, cross-over trial of nebulized amiloride was performed in 23 patients with cystic fibrosis. Amiloride or placebo was administered four times daily for two six month periods. Existing treatment was continued, and any infective exacerbations treated in the usual way. Fourteen patients completed the study. No significant changes occurred in forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate during either treatment period. The frequency of infective exacerbations was also not different in either treatment period. We were thus unable to confirm the benefit shown in the only other clinical trial of nebulized amiloride in cystic fibrosis and conclude that, in the presence of established treatment for cystic fibrosis lung disease, nebulized amiloride offers no additional clinical benefit.
在囊性纤维化（CF）中，气道上皮钠吸收增加了2至3倍。由于钠通道阻滞剂氨氯吡咪可抑制钠吸收，我们的目的是评估其对囊性纤维化的治疗益处。对23例囊性纤维化患者进行了一项雾化氨氯吡咪的随机、双盲、安慰剂对照、交叉试验。氨氯吡咪或安慰剂每日给药4次，为期两个6个月周期。继续现有治疗，并以常规方式治疗任何感染性加重情况。14名患者完成了研究。在任何一个治疗期间，一秒用力呼气量、用力肺活量、血氧饱和度、体重、痰量、培养及流变学、血清尿素、电解质、白细胞计数和红细胞沉降率均无显著变化。两个治疗期间感染性加重的频率也没有差异。因此，我们无法证实雾化氨氯吡咪在囊性纤维化的唯一另一项临床试验中所显示的益处，并得出结论，在存在既定的囊性纤维化肺病治疗方法的情况下，雾化氨氯吡咪没有额外的临床益处。
